Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Sickle Cell Pharmacy Override topic
No spam. Unsubscribe anytime.
Committee tables bill to ease pharmacy prior‑authorization overrides for sickle‑cell pain meds
Summary
A bill to let pharmacists dispense certain opioid prescriptions for sickle‑cell crises without insurer hard overrides was tabled by the committee, 4‑3.
Delegate Waksman presented a bill intended to ease access to short‑term opioid prescriptions for patients with sickle‑cell disease by allowing pharmacists to fill prescriptions without initiating insurer hard overrides when a drug utilization review (DUR) stop is triggered. Waksman said the change was intended for acute pain crises when patients cannot reach a prescriber for an insurer‑required override during nights or weekends.
Nut graf: Supporters said the practice would reduce dangerous delays in pain relief for sickle‑cell patients; opponents and PBM representatives cautioned that opioids have significant safety risks and that federal rules and pharmacy‑benefit manager (PBM) systems may complicate administration. Doug Grama (Virginia Association of Health Plans) said the mechanism needs research to determine whether federal opioid/controlled‑substance safeguards would permit a state‑level change, and Karen Addison (PCMA) urged balancing access with safety.
Outcome: The subcommittee voted 4‑3 to lay the bill on the table (effectively tabling it) after receiving mixed testimony and requests for technical work on administration and federal compliance. Supporters agreed to continue discussions with insurers and PBMs on implementation details.
Ending: Because the bill was tabled by committee, it will not move forward during this session; the patron and stakeholders said they would pursue technical work over the interim to address federal compliance and implementation questions.
